Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
BTQ 73x. Kommt jetzt Delta?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 | ISIN: US75886F1075 | Ticker-Symbol: RGO
Tradegate
11.06.26 | 21:41
529,40 Euro
+1,57 % +8,20
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
527,00528,0011.06.
525,50529,7011.06.

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy5
MiRegeneron-backed Parabilis surges after record-setting IPO3
DiREGENERON PHARMACEUTICALS INC: Struktur im Fokus1
04.06.Alvotech seeks U.S. nod for biosimilars to J&J's Simponi and Regeneron's Eylea again15
04.06.REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics17
04.06.Regeneron backed Parabilis seeks up to $476M in U.S. IPO10
04.06.Regeneron to present clinical data at diabetes and endocrine meetings6
04.06.Regeneron and CytomX extend cancer therapy partnership to $4bn deal22
03.06.CytomX-Aktie im Aufwind nach erweiterter Forschungskooperation mit Regeneron10
03.06.Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact9
03.06.CytomX gains as licensing deal with Regeneron expands4
03.06.CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer442- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive...
► Artikel lesen
01.06.Is Regeneron Pharmaceuticals Stock Underperforming the Dow?12
01.06.Regeneron Cancer Drug Shows New Promise in a Rare Disease… and Maybe More14
28.05.Regeneron, Gilead therapies eyed as potential Ebola treatments by WHO23
28.05.Regeneron Pharmaceuticals, Inc.: Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak21
25.05.Look Out Below for HIMS and Regeneron27
22.05.Regeneron Pharmaceuticals's Genetic Hearing Loss Drug Wins EMA Filing Acceptance334WASHINGTON (dpa-AFX) - Friday, Regeneron Pharmaceuticals, Inc. (REGN) announced that Otarmeni has been accepted by European Medicines Agency for review under Accelerated Assessment the Marketing...
► Artikel lesen
22.05.EMA accepts Regeneron's gene therapy for rare hearing loss9
22.05.Regeneron Pharmaceuticals, Inc.: Otarmeni (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss391TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment...
► Artikel lesen
Weiter >>
339 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5